疑似肺栓塞导致心脏骤停时溶栓治疗的回顾性分析
本研究为回顾性描述性队列,纳入32例在急诊科活动性心脏骤停期间接受阿替普酶或替奈普酶的成人患者,药物选择与剂量由主治医师决定。多数为有目击的院外心脏骤停、不可除颤心律,平均年龄63岁,骤停前最常见症状为呼吸困难。阿替普酶中位剂量50 mg,替奈普酶中位剂量45 mg;11例溶栓后恢复自主循环,其中7例存活至入院,最终仅2例存活出院;除1例外所有患者住院期间发生大出血。作者认为需进一步研究以优化这一致命情况的处理。
要点
- 32例疑似肺栓塞致心脏骤停成人接受溶栓,阿替普酶中位剂量50 mg、替奈普酶中位剂量45 mg,由主治医师决定药物与剂量。
- 溶栓后11例恢复自主循环,其中7例存活至入院,最终仅2例存活出院。
- 除1例外所有患者住院期间发生大出血,出血风险极高。
- 恢复自主循环的11例中9例用阿替普酶(5例存活至入院、均大出血),2例用替奈普酶(均存活至入院、1例大出血),两组各1例存活出院。
- 多数为有目击的院外心脏骤停、不可除颤心律,平均年龄63岁,骤停前最常见为呼吸困难。
适用人群与场景
- 急诊科活动性心脏骤停的成人患者,临床怀疑大块肺栓塞(疑似肺栓塞)。
- 本研究为32例接受阿替普酶或替奈普酶的回顾性队列;多数为有目击的院外心脏骤停、不可除颤心律,平均年龄63岁。
处置流程与药物剂量
- 溶栓药物选择与剂量由主治医师决定;阿替普酶中位剂量50 mg,替奈普酶中位剂量45 mg。
研究设计与关键结果
- 回顾性描述性队列,32例成人于急诊科活动性心脏骤停期间接受阿替普酶或替奈普酶。
- 多数为有目击的院外心脏骤停、不可除颤心律,平均年龄63岁,骤停前最常见症状为呼吸困难。
- 阿替普酶中位剂量50 mg,替奈普酶中位剂量45 mg;药物选择与剂量由主治医师决定。
- 11例溶栓后恢复自主循环,其中7例存活至入院,最终仅2例存活出院。
- 除1例外所有患者住院期间发生大出血。
- 恢复自主循环的11例中,9例用阿替普酶(其中5例存活至入院,5例均发生大出血),2例用替奈普酶(均存活至入院,1例发生大出血);两组各1例存活出院。
证据类型、等级与局限
- 证据类型:回顾性、描述性队列研究。
- 作者结论:尽管给予溶栓,存活至入院及后续存活出院者仅占很小比例;需进一步研究以优化这一致命情况的处理。
- 局限:原文未报告局限性。
对床旁实践的改变
- 本研究提示疑似大块肺栓塞所致心脏骤停患者接受溶栓后恢复自主循环、存活至入院及存活出院者仅占很小比例,且除1例外均发生大出血。
- 作者认为需进一步研究以优化这一致命情况的处理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Massive pulmonary embolism (PE) causing obstructive shock can lead to circulatory failure and cardiac arrest. There is a paucity of data describing current practice around thrombolytic use and outcomes in this patient population.
OBJECTIVE: The objective of this study was to describe the characteristics and outcomes of patients who received a thrombolytic agent during cardiac arrest due to suspected PE, including efficacy and safety.
METHODS: This study was a retrospective, descriptive cohort of 32 adult patients who received alteplase or tenecteplase in the emergency department during active cardiac arrest. Agent selection and dosing were at the discretion of the primary provider.
RESULTS: Most patients presented with a witnessed out-of-hospital cardiac arrest with a non-shockable rhythm. The mean age was 63 years. Dyspnea was most commonly reported prior to cardiac arrest. The median dose for alteplase was 50 mg and for tenecteplase was 45 mg. Eleven patients achieved ROSC after thrombolytic administration; seven of these patients survived to hospital admission. All but one patient experienced a major bleeding event during admission. Ultimately, only two patients survived to hospital discharge. A subgroup analysis compared patients administered alteplase to those administered tenecteplase. Nine of the eleven patients that achieved ROSC were administered alteplase, five of which survived to hospital admission. All five patients experienced a major bleeding event. Two of the eleven patients that achieved ROSC were administered tenecteplase, both of which survived to hospital admission. One patient experienced a major bleeding event. Ultimately, only one patient in each group survived to hospital discharge.
CONCLUSION: This study provides new data regarding the outcomes of thrombolytic therapy in patients experiencing cardiac arrest due to suspected massive PE. Despite administration of thrombolytics, survival to hospital admission and subsequent survival to hospital discharge were seen in only a very small proportion of patients. Further research is necessary to optimize the management of this life-threatening condition.
参考来源
- Jansen A, Schmitt CJ, Cabrera D, et al. Retrospective review of thrombolytic use for cardiac arrest due to suspected pulmonary embolism. Am J Emerg Med. 2025. PMID: 40279831. doi:10.1016/j.ajem.2025.04.036
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。